In brief: Prima, SciGen, Sonic
Thursday, 30 June, 2005
The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
SciGen (ASX:SIE) managing director and CEO Mark Compton will leave the company on August 5. While he will remain as CEO till then, he has resigned as a director, effective June 29. SciGen is searching for a new CEO who is likely to be based in Asia.
Former CEO and executive director of the Melbourne Pathology Group, Lou Panaccio has joined the board of Sonic Healthcare (ASX:SHL) as a non-executive director. He will also replace Colin Jackson as a member of the Audit Committee.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
